Endogenous BK stimulates ischemically sensitive abdominal visceral C fiber afferents through kinin B2 receptors.
Abdominal ischemia and reperfusion reflexly activate the cardiovascular system. In the present study, we evaluated the role of endogenously produced bradykinin (BK) in the stimulation of ischemically sensitive visceral afferents. Single-unit activity of abdominal visceral C fiber afferents was recorded from the right thoracic sympathetic chain of anesthetized cats during 5 min of abdominal ischemia. Abdominal ischemia increased the portal venous plasma BK level from 49 +/- 10 to 188 +/- 66 pg/ml (P < 0.05). Injection of BK (1 microgram/kg ia) into the descending aorta significantly increased impulse activity (0.88 +/- 0.16 impulses/s) of 10 C fibers, whereas a kinin B1-receptor agonist, des-Arg9-BK (1 microgram/kg), did not alter the discharge rate. Inhibition of kininase II activity with captopril (4 mg/kg i.v.) potentiated impulse activity of 14 ischemically sensitive C fibers (0.44 +/- 0.09 vs. precaptopril, 0.33 +/- 0.08 impulses/s; P < 0.05). In addition, a kinin B2-receptor antagonist (NPC-17731; 40 micrograms/kg i.v.) attenuated activity of afferents during ischemia (0.39 +/- 0.08 vs. pre-NPC-17731, 0.72 +/- 0.13 impulses/s; P < 0.05) and eliminated the response of 10 C fibers to BK. Another kinin B2-receptor antagonist, Hoe-140 (30 micrograms/kg iv), had similar inhibitory effects on six other ischemically sensitive C fibers. In 15 separate cats treated with aspirin (50 mg/kg i.v.), Hoe-140 (30 micrograms/kg i.v.) attenuated impulse activity of only 3 of 16 ischemically sensitive C fibers. These data suggest that BK produced during abdominal ischemia contributes to the stimulation of ischemically sensitive visceral C fiber afferents through kinin B2 receptors.(ABSTRACT TRUNCATED AT 250 WORDS)
Pan
H L
HL
Department of Internal Medicine, University of California, Davis 95616.
Stahl
G L
GL
Rendig
S V
SV
Carretero
O A
OA
Longhurst
J C
JC
D000344:Afferent Pathways / Q000187:drug effects / Q000503:physiopathology*; D000818:Animals; D001241:Aspirin / Q000494:pharmacology; D001920:Bradykinin / Q000031:analogs & derivatives / Q000097:blood / Q000494:pharmacology / Q000502:physiology*; D065168:Bradykinin Receptor Antagonists; D002216:Captopril / Q000494:pharmacology; D002415:Cats; D007511:Ischemia / Q000503:physiopathology*; D009412:Nerve Fibers / Q000187:drug effects / Q000502:physiology*; D009842:Oligopeptides / Q000494:pharmacology; D011169:Portal Vein; D018002:Receptors, Bradykinin / Q000502:physiology*; D014781:Viscera / Q000098:blood supply* / Q000294:innervation*
D065168:Bradykinin Receptor Antagonists; D009842:Oligopeptides; D018002:Receptors, Bradykinin; C071327:NPC 17731; C024626:bradykinin, des-Arg(9)-; C065679:icatibant; D002216:Captopril; D001241:Aspirin; D001920:Bradykinin